Skip to main content
All lobbying filings

LABORATORY CORPORATION OF AMERICA HOLDINGS

Lobbying for LABORATORY CORPORATION OF AMERICA HOLDINGS

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Jan 13, 2026.
 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 1, 2025
Expenses
$270,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
North Carolina

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; Federal policy relating to oversight of laboratory-developed tests; Section 71120 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to modifying cost sharing requirements for certain expansion individuals under the Medicaid program; H.R. 3514/S.1816, the Improving Seniors Timely Access to Care Act, provisions relating to prior authorization of services to Medicare Advantage beneficiaries; S. 2355, the Patients Deserve Price Tags Act, provisions relating to lab test price transparency; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to medical laboratory personnel eligibility for the National Health Service Corps and federal grants for lab personnel training; Federal policy relating to implementation of Medicare reimbursement cuts under the Statutory Pay-As-You-Go Act of 2010, Pub. L. 111-139; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.

Sections 70301, 70302, 70412(b), and 70603 of H.R. 1, An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14, provisions relating to extension of bonus depreciation under Internal Revenue Code Section 168(k), immediate deductibility of domestic research and development expenses under Internal Revenue Code Section 174, individual deductibility of employer-funded tuition assistance under Internal Revenue Code Section 127, and executive compensation under Internal Revenue Code Section 162(m), respectively; Title VII, Subtitle A, Chapter 3, Subchapter B of such Act, provisions relating to treatment of tax credits and reporting simplification under international tax law and guidance; and federal policy relating to income tax rates for corporations and income tax deductibility of corporate state and local taxes.

 Bills named in this filing 8
  • H.R. 5269
    RESULTS Act
  • S. 2761
    RESULTS Act
  • H.R. 1
    One Big Beautiful Bill Act
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • H.R. 3514
    Improving Seniors’ Timely Access to Care Act of 2025
  • S. 1816
    Improving Seniors’ Timely Access to Care Act of 2025
  • S. 2355
    Patients Deserve Price Tags Act
  • H.R. 5444
    Medical Laboratory Personnel Shortage Relief Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem